News

Memory Pharmaceuticals is currently conducting a Phase II trial of R3487/MEM 3454 in cognitive impairment associated with schizophrenia (CIAS), and the companies have agreed to expand the study

Depomed’s Phase III registration program for Gabapentin GR in menopausal hot flashes includes two randomized, double-blind, placebo-controlled studies of approximately 540 patients per study. In each study, patients

Under the terms of the agreement, Biovail has paid $100 million to acquire 100% of Prestwick Pharmaceuticals and related license rights. Beyond Xenazine, the acquisition also provides Biovail

The Phase IIb study is a randomized, double-blind, placebo-controlled study that is designed to assess the safety and efficacy of Xiaflex, when administered two times a week every

Dr Soni joins Amarin from Pfizer where he held a number of leadership roles in Pfizer global R&D in both experimental medicine and late stage development. Amarin has

The CINtec cytology kit is an immuno-cytochemistry assay for the qualitative detection of the p16INK4a antigen on cervical cytology preparations. It is intended to be used as an

The agreements, which provide Signum with combined upfront license fees and investment funds in the seven figures, give Rohto a non-exclusive right to develop and sell products in

Merck’s decision triggers an additional $9 million payment to SurModics from Merck. Merck’s decision to discontinue the collaboration was made following a strategic review of its business and

According to the company, the SmoothShapes system uses a proprietary technology called Photomology that features an unique mechanism of action combining dynamic laser and light energy with mechanical